Abstract 470P
Background
Due to its high propensity for metastasis and lack of durable response to therapy, several biomarkers have been studied to help predict outcomes in patients with Small Cell Lung Cancer (SCLC). These biomarkers aid the clinicians in their treatment decisions among these patients. Neuron-specific enolase (NSE), can be used in supporting a diagnosis of SCLC. However, little is known on its prognostic significance due to the limited number of studies conducted. Carcino-embryonic antigen (CEA) can be used in treatment monitoring and prognostication in several cancers. Few studies have been conducted among SCLC patients investigating its prognostic significance. Moreover, no meta-analysis has been conducted on this outcome. Vascular endothelial growth factor (VEGF) plays an important role in the dissemination of malignancy. Although serum VEGF is found many cancer patients, little is known about its prognostic significance among SCLC. Moreover, no meta-analysis has been conducted on this outcome. This study aims to conduct a systematic review and meta-analysis on the prognostic significance of the CEA, NSE and VEGF on SCLC.
Methods
A systematic review was conducted to examine the prognostic significance of three biomarkers in the prognosis of SCLC: CEA, VEGF and NSE. Systematic search was done using Pubmed, Cochraine and EMBASE for articles published until July 1, 2019. Seventeen studies with a total of 3, 973 patients were included in the analysis. The primary outcome of interest was Overall Survival in SCLC. Data was summarized using RevMan 5.3. Preplanned subgroup analysis was done on the type of study and the statistic used.
Results
High CEA (HR 1.28 95%CI 1.10-1.50, p < 0.001, I2 45%) and VEGF (HR 1.84 CI 1.21-2.78 p = 0.004, I2 52%) were both associated with poor overall survival. NSE was associated with poor overall survival based on pooled retrospective studies (HR 1.42 CI 1.22-1.67, p < 0.00001, I2 34%) and prospective studies (RR 1.68 CI 1.40-2.02, p < 0.00001, I2 50%). Pooled HR for prospective studies was not significant (HR 2.32 CI 0.96-5.56, p = 0.06, I2 83%).
Conclusions
High NSE, CEA and VEGF may be used as prognostic biomarkers of poor survival in patients with SCLC. Further randomized studies may confirm these findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D.B.L. Sacdalan: Honoraria (self): Merck. All other authors have declared no conflicts of interest.
Resources from the same session
41P - Clinical verification on the relationship between serum lipid metabolism and the immune microenvironment in breast cancer patients
Presenter: Wataru Goto
Session: Poster display session
Resources:
Abstract
42P - Genome wide copy number analysis of circulating tumour cells in breast cancer liver metastasis
Presenter: Saber Imani
Session: Poster display session
Resources:
Abstract
43P - A hotspot variants p.H1047R and p.H1047L in p110α/ΔNp63α complex affects structure, function and contributes to susceptibility metastatic breast cancer
Presenter: Zou Linglin
Session: Poster display session
Resources:
Abstract
44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
45P - The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location
Presenter: Hubert Beaumont
Session: Poster display session
Resources:
Abstract
46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics
Presenter: Aditia Romadhoni
Session: Poster display session
Resources:
Abstract
47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer
Presenter: MAYUKO MIKI
Session: Poster display session
Resources:
Abstract
48P - Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis
Presenter: Ahmad Murtadha
Session: Poster display session
Resources:
Abstract
49P - Biochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
50P - Prognostic factors of recurrence or distant metastasis in elderly breast cancer patients
Presenter: Seungju Lee
Session: Poster display session
Resources:
Abstract